Category
ADC Therapy Antibody Therapy Cell & Gene Therapy Oncolytic Virotherapy Others Protein Therapy Small Molecule Vaccine
2025/11/13Flyer Cell & Gene Therapy
Based on a pioneering mRNA/LNP delivery platform, an in vivo anti-CD18/BCMA mRNA/LNP CAR-T is being developed for autoimmune diseases.
2025/12/18Flyer Small Molecule
PARP inhibitors are currently in the preclinical development stage, aiming to address the challenges of systemic toxicity and limited blood-brain barrier (BBB) penetration.
2025/12/26Flyer Antibody Therapy
A proprietary AI-powered discovery platform can accelerate the development of next-generation multi-specific antibodies, monoclonal antibodies, and nanobodies. A broad range of PCC molecules are being developed at an accelerated pace in early-stage discovery.
2026/01/10Flyer Cell & Gene Therapy
Dual-AAV vector-based gene therapies are currently undergoing clinical trials for various conditions, including ophthalmic, neuromuscular, and inherited metabolic diseases.
2026/01/20Flyer Others
In alignment with global "sugar reduction" and "zero additive" trends, transgenic crops with high expression of sweet proteins are being developed as a systematic solution for natural sugar substitution at the source.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial cross-border BD consulting service to encompass segments in equity investment and project incubation.
 |
Protheragen Inc. |
 |
Quick Links |
